海思科医药集团股份有限公司 独立董事候选人声明 证券代码：002653 证券简称：海思科 公告编号：2023-094 声明人岳琳 ，作为海思科医药集团股份有限公司第五届董事会 独立董事候选人，现公开声明和保证，本人与该公司之间不存在任 何影响本人独立性的关系，且符合相关法律、行政法规、部门规章、 规范性文件和深圳证券交易所业务规则对独立董事候选人任职资格 及独立性的要求，具体声明如下： 一、本人不存在《中华人民共和国公司法》第一百四十六条等 规定不得担任公司董事的情形。 是 □ 否 如否，请详细说明：_____________________________ 二、本人符合中国证监会《上市公司独立董事规则》规定的独 立董事任职资格和条件。 是 □ 否 如否，请详细说明：_____________________________ 三、本人符合该公司章程规定的独立董事任职条件。 是 □ 否 如否，请详细说明：_____________________________ 四、本人已经参加培训并取得证券交易所认可的相关证书。 是 □ 否 如否，请详细说明：_____________________________ 五、本 ...

海思科医药集团股份有限公司独立董事 对相关事项发表的独立意见 根据《上市公司独立董事规则》《深圳证券交易所股票上市规则 （2022 年修订）》《深圳证券交易所上市公司自律监管指引第 1 号 ——主板上市公司规范运作》及《海思科医药集团股份有限公司章程》 等的有关规定，作为海思科医药集团股份有限公司（以下简称"公 司"）独立董事，我们对公司第四届董事会第五十三次会议审议的相 关事项发表如下独立意见： 关于对公司董事会换届提名第五届董事会董事候选人的独立意 见 独立董事：乐军 TENG BING SHENG YAN JONATHAN JUN 2023 年 8 月 10 日 2 1、本次公司董事会换届选举的非独立董事、独立董事候选人的 提名已征得被提名人本人同意，且其任职资格已经过公司董事会提名 委员会审查，提名程序符合《公司法》、《公司章程》等相关法律法 规的规定，表决程序合法有效； 2、本次提名王俊民、范秀莲、郑伟、严庞科为公司第五届董事 会非独立董事候选人，提名乐军、岳琳、曹传德为公司第五届董事会 独立董事候选人，上述候选人均具备相关法律法规所规定的上市公司 董事任职资格，未发现有、也未收到中国证监会及其他有 ...

提名人海思科医药集团股份有限公司第四届董事会现就提名【曹 传德】为海思科医药集团股份有限公司第五届董事会独立董事候选人 发表公开声明。被提名人已书面同意出任海思科医药集团股份有限公 司第五届董事会独立董事候选人。本次提名是在充分了解被提名人职 业、学历、专业资格、详细的工作经历、全部兼职等情况后作出的， 本提名人认为被提名人符合相关法律、行政法规、部门规章、规范性 文件和深圳证券交易所业务规则对独立董事候选人任职资格及独立 性的要求，具体声明如下： 证券代码：002653 证券简称：海思科 公告编号：2023-095 海思科医药集团股份有限公司 独立董事提名人声明 一、被提名人不存在《中华人民共和国公司法》第一百四十六条 等规定不得担任公司董事的情形。 是 □ 否 如否，请详细说明：______________________________ 二、被提名人符合中国证监会《关于在上市公司建立独立董事制 度的指导意见》规定的独立董事任职资格和条件。 是 □ 否 如否，请详细说明：______________________________ 三、被提名人符合公司章程规定的独立董事任职条件。 是 □ 否 如否，请详细 ...

非公开发行限售股解除限售暨上市流通的核查意见 华泰联合证券股份有限公司（以下简称"华泰联合证券"或"保荐机构"）作为 海思科医药集团股份有限公司（以下简称"海思科"或"公司"）非公开发行股票的 保荐机构，根据《证券发行上市保荐业务管理办法》、《深圳证券交易所股票上市 规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》、《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等有关规 定，对海思科本次非公开发行限售股解除限售暨上市流通的事项进行了审阅、核 查，具体情况如下： 一、本次解除限售股份取得的基本情况 （一）本次限售股份核准情况 华泰联合证券有限责任公司 关于海思科医药集团股份有限公司 公司于 2022 年 4 月 25 日收到中国证券监督管理委员会（以下简称"中国证 监会"）出具的《关于核准海思科医药集团股份有限公司非公开发行股票的批复》 （证监许可〔2022〕869 号），核准公司非公开发行不超过 4,000 万股新股，发生 转增股本等情形导致总股本发生变化的，可相应调整本次发行数量。 （二）本次限售股股份登记及锁定期安排 公司本次非公开发行股份数量为 40,0 ...

证券代码：002653 证券简称：海思科 公告编号：2023-088 海思科医药集团股份有限公司 关于非公开发行限售股解除限售暨上市流通的 一、本次解除限售股份取得的基本情况 （一）本次限售股份核准情况 海思科医药集团股份有限公司（以下简称"公司"）于 2022 年 4 月 25 日收到中国证券监督管理委员会（以下简称"中国证监会"） 出具的《关于核准海思科医药集团股份有限公司非公开发行股票的批 复》（证监许可〔2022〕869 号），核准公司非公开发行不超过 4,000 万股新股，发生转增股本等情形导致总股本发生变化的，可相应调整 本次发行数量。 （二）本次限售股股份登记及锁定期安排 1 提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次解除限售的股份为非公开发行限售股，解除限售股份为 为 40,000,000 股，占目前公司总股本的 3.5903%。 2、本次解除限售的限制性股票的上市流通日期为 2023 年 8 月 10 日。 公司本次非公开发行股份数量为 40,000,000 股，已于 2023 年 2 月 10 日在深圳 ...

海思科医药集团股份有限公司投资者关系 活动记录表 编号：20230509 | 投资者关系活动类别 | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 ■业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | 活动参与人员 | 投资者网上提问 | | 时间 | 2023 年 5 月 9 日 (周二)下午 15:00-17:00 | | 地点 | 公 司 通 过 全 景 网 " 投 资 者 关 系 互 动 平 台 " | | | （https://ir.p5w.net）采用网络远程的方式召开业绩说 | | | 明会 | | 形式 | 网络会议 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、请问贵司和哪几所大学有研发当面的合作？ 答：公司目前与四川大学等高校有开展合作，后续也在探 索与更多的高校就人才培养、研发项目等方面展开更多的 | | | 合作。 2、请问环泊酚国外情况如何？ | | | 答：HSK3486 适应症麻醉诱导（IGA）的第一项美国Ⅲ期 | | 交流内容及具体问答 | 临床试 ...

1 证券代码：002653 证券简称：海思科 公告编号：2023-053 海思科医药集团股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）《2022 年年 度报告》及其摘要已于 2023 年 4 月 18 日刊登在巨潮资讯网等公司指 定信息披露媒体。 为便于投资者进一步了解公司经营情况，公司定于 2023 年 5 月 9 日（星期二）15:00-17:00 在全景网举办 2022 年度业绩说明会，本 次业绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投 资者关系互动平台"（https://ir.p5w.net）参与本次年度业绩说明 会。 出席本次业绩说明会的人员有：公司董事长王俊民先生、独立董 事乐军先生、董事会秘书王萌先生、财务总监段鹏先生、保荐代表人 王正睿先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业 绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建 议。投资者可于 2023 年 5 月 8 日（星期一）12： ...

Revenue and Profit - The company's revenue for Q1 2023 was ¥623,643,966.44, representing a 10.97% increase compared to ¥562,010,168.13 in the same period last year[3] - Net profit attributable to shareholders was ¥28,749,239.94, up 9.72% from ¥26,203,211.37 year-on-year[3] - The total revenue for Q1 2023 was approximately ¥792.96 million, an increase from ¥630.37 million in Q1 2022, representing a growth of about 25.8%[14] - The net profit attributable to the parent company for Q1 2023 was ¥28.75 million, compared to ¥26.20 million in Q1 2022, reflecting an increase of approximately 9.7%[13] - The operating profit for Q1 2023 was ¥26.29 million, slightly up from ¥25.23 million in Q1 2022, indicating a growth of about 4.2%[12] - The total comprehensive income for Q1 2023 was ¥84.17 million, compared to a loss of ¥4.46 million in Q1 2022, marking a significant turnaround[13] Cash Flow - The net cash flow from operating activities improved significantly, totaling ¥62,064,077.64, a 174.94% increase from a negative cash flow of ¥82,814,972.24 in the same period last year[3] - The cash flow from operating activities for Q1 2023 was ¥792.96 million, significantly higher than ¥630.37 million in Q1 2022, showing a growth of about 25.8%[14] - Total cash inflow from operating activities reached ¥817,203,816.73, compared to ¥649,456,733.93 in the same period last year, reflecting a year-over-year increase of approximately 26%[15] - Cash outflow from operating activities was ¥755,139,739.09, slightly higher than ¥732,271,706.17 in Q1 2022, indicating a 3% increase[15] - The net cash flow from investing activities was -¥204,190,501.62, showing a marginal improvement from -¥204,804,378.89 in Q1 2022[15] - Cash inflow from financing activities totaled ¥896,612,751.62, a substantial increase from ¥630,381,826.12 in the previous year, marking an increase of approximately 42%[15] - The net cash flow from financing activities was ¥487,552,826.46, compared to ¥312,876,285.61 in Q1 2022, representing a growth of about 56%[15] Assets and Liabilities - Total assets as of March 31, 2023, were ¥6,479,155,437.62, reflecting a 7.17% increase from ¥6,045,955,274.42 at the end of the previous year[3] - The total current assets at the end of Q1 2023 amounted to CNY 2,396,324,149.07, up from CNY 2,053,646,749.91 at the beginning of the year, indicating an increase of about 16.7%[9] - The total liabilities decreased to CNY 2,466,085,302.22 from CNY 2,912,530,673.63, showing a reduction of about 15.3%[10] - The company's long-term equity investments rose to CNY 192,205,071.00 from CNY 185,109,765.36, reflecting an increase of approximately 3.0%[9] - The company's total non-current liabilities decreased to CNY 1,062,816,168.38 from CNY 1,423,976,752.09, indicating a reduction of approximately 25.4%[10] Shareholder Equity - Shareholders' equity attributable to the parent company increased by 29.02%, amounting to ¥3,916,726,019.63 compared to ¥3,035,744,121.70 at the end of the previous year[3] - The total owner's equity increased to CNY 4,013,070,135.40 from CNY 3,133,424,600.79, representing a growth of about 28.1%[10] Expenses - Research and development expenses for Q1 2023 amounted to ¥91.51 million, an increase from ¥85.92 million in Q1 2022, showing a rise of approximately 6.1%[12] - The sales expenses for Q1 2023 were ¥226.65 million, compared to ¥197.36 million in Q1 2022, representing an increase of approximately 14.9%[12] - The tax expenses for Q1 2023 were ¥2.81 million, compared to ¥2.33 million in Q1 2022, indicating an increase of approximately 20.5%[12] - Payments for employee compensation increased to ¥226,144,832.28 from ¥183,123,898.94, reflecting a growth of about 23.5%[15] - Tax payments rose to ¥83,552,327.77 from ¥44,103,638.71, indicating an increase of approximately 89% year-over-year[15] Investment and Losses - The company experienced a 375.03% decrease in investment income, reporting a loss of ¥9,512,591.88 due to net losses from associates[5] - The net investment loss for Q1 2023 was ¥9.51 million, worsening from a loss of ¥2.00 million in Q1 2022[12] - The total amount of non-recurring gains and losses for the period was ¥2,721,502.80, after accounting for tax effects[4]

Financial Performance - The company's operating revenue for 2022 was CNY 3,015,294,339.82, representing an increase of 8.73% compared to CNY 2,773,314,884.86 in 2021[12]. - The net profit attributable to shareholders for 2022 was CNY 277,002,781.63, a decrease of 19.72% from CNY 345,058,649.45 in 2021[12]. - The net profit after deducting non-recurring gains and losses was CNY 95,553,398.52, which is a significant increase of 171.42% compared to CNY 35,205,086.23 in 2021[12]. - The basic earnings per share for 2022 was CNY 0.26, down 18.75% from CNY 0.32 in 2021[12]. - The total assets at the end of 2022 were CNY 6,045,955,274.42, an increase of 20.79% from CNY 5,005,285,084.31 at the end of 2021[12]. - The net assets attributable to shareholders at the end of 2022 were CNY 3,035,744,121.70, reflecting a growth of 6.82% from CNY 2,841,929,513.83 at the end of 2021[12]. - The company reported a significant increase in cash flow from operating activities, with a net cash flow of CNY 94,546,036.93, up 164.08% from CNY 35,801,459.91 in 2021[12]. - The company achieved a revenue of 3.015 billion yuan in 2022, an increase of 8.73% year-on-year, while the net profit attributable to shareholders decreased by 19.72% to 277 million yuan[36]. Market and Product Development - The company is focusing on innovation in drug development, with an increase in the number of IND and NDA applications over the past five years[19]. - The company is committed to expanding its market presence and enhancing its product offerings in response to evolving industry dynamics[19]. - The company is actively advancing the international clinical trial of its anesthetic drug HSK3486 in the United States[22]. - The company has submitted NDA for its diabetes peripheral neuropathy drug HSK16149 and type 2 diabetes treatment drug HSK7653, which are currently under review[22]. - The company is recognized as one of the top 100 Chinese pharmaceutical companies and has achieved an AAA credit rating in the pharmaceutical industry[22]. - The company is focused on providing innovative specialty drugs across various therapeutic areas, including anesthesia, oncology, and cardiovascular health[23]. - The company has established a comprehensive marketing innovation system focused on patient-centered and academic marketing, with eight major business divisions[28]. - The company has established multiple technical platforms for drug development, including platforms for poorly soluble formulations and inhalation formulations[35]. Research and Development - The company has a research and development team of over 900 personnel, with approximately 37% holding master's degrees or higher, and a high proportion of PhD holders in core departments reaching 60%[33]. - The company has undertaken 6 national-level major scientific research projects, including the clinical research of the new GABAA receptor agonist HSK3486 and innovative research on new drugs for AIDS and hepatitis B prevention[32]. - The R&D team has published nearly 40 papers in core journals, focusing on fields such as anesthesia analgesia and diabetes[32]. - The company has a strong pipeline with multiple products in various stages of clinical trials, enhancing its competitive edge[57]. - R&D investment reached approximately 958 million yuan in 2022, with expectations for further growth in 2023 to support the introduction of innovative drug products[118]. Governance and Management - The company has implemented a comprehensive governance structure, ensuring compliance with relevant laws and regulations, and enhancing operational efficiency[86]. - The company has established independent personnel management systems and signed labor contracts with employees, ensuring no interference from controlling shareholders[88]. - The company has a diverse board with members holding positions in various other organizations, including independent directors and executives in different sectors[97][98]. - The company emphasizes a performance-based salary structure for its senior management, which is reviewed and adjusted annually[99]. - The company has established a robust governance structure with a mix of experienced professionals from various sectors, ensuring comprehensive oversight and strategic guidance[97][98]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities, adhering to various environmental standards and regulations[129]. - The company achieved a total emission of 0.515 tons of particulate matter, which is below the approved limit of 3.34 tons[134]. - The company has obtained environmental impact assessment approvals for projects in Liaoning, Sichuan, and Shenyang, with specific registration numbers issued in July 2022[132]. - The company has implemented wastewater treatment measures that ensure all discharges meet or exceed local environmental standards, reflecting a commitment to sustainability[135]. - The company is actively monitoring and managing its emissions to align with regulatory requirements and improve environmental performance[136]. Social Responsibility - The company actively participated in social welfare activities, including donations to special education schools and support for frontline police officers, totaling over 10,000 yuan in various contributions[149]. - The company plans to invest 120 million yuan in a new chemical drug production base in Shannan City, Tibet, which is expected to create over 100 jobs for local farmers and students[150]. - The company provided 1,000 square meters of office space for free to support entrepreneurship for impoverished university students in Shannan City[150]. - The company emphasizes the protection of employee rights and has established a comprehensive compensation and benefits management system to ensure fair treatment and a harmonious labor relationship[149]. Future Outlook - The company plans to apply for IND for 3-4 innovative drugs, including those in oncology and analgesia fields, while also launching 5-10 new projects[77]. - The company aims to become the most trusted international pharmaceutical enterprise, focusing on "R&D + marketing" dual-driven strategy and expanding market presence with innovative drugs like HSK7653 and HSK16149[76]. - The company plans to distribute at least 20% of its distributable profits as cash dividends during profit distribution[155].